

Ketamine Assisted Psychotherapy

Search strategy:

((DE "Psychotherapy" OR DE "Adolescent Psychotherapy" OR DE "Analytical Psychotherapy" OR DE "Brief Psychotherapy" OR DE "Child Psychotherapy" OR DE "Eclectic Psychotherapy" OR DE "Experiential Psychotherapy" OR DE "Expressive Psychotherapy" OR DE "Geriatric Psychotherapy" OR DE "Gestalt Therapy" OR DE "Group Psychotherapy" OR DE "Humanistic Psychotherapy" OR DE "Individual Psychotherapy" OR DE "Integrative Psychotherapy" OR DE "Interpersonal Psychotherapy" OR DE "Psychoanalysis") OR AB psychotherap*)

AND

(DE "Ketamine" OR AB ketamine)

Databases: Medline, PsychINFO

Limits: 2015-2020, English language

Contents

Top Articles	3
Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy.	3
A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial.	3
d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study.	3
Subanesthetic Dose Ketamine in Posttraumatic Stress Disorder: A Role for Reconsolidation During Trauma-Focused Psychotherapy?	3
Toward specific ways to combine ketamine and psychotherapy in treating depression.....	4
A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial.	4
Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder.....	4
Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.	4
Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression.	4
Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.....	5
PsychINFO	6

Translating molecular and neuroendocrine findings in posttraumatic stress disorder and resilience to novel therapies.....	6
Exploring brain-derived neurotrophic factor Val66Met polymorphism and extinction learning-based treatment outcome in obsessive-compulsive disorder: A pilot study.	6
Ketamine abuse potential and use disorder.	6
Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?	6
Medline	7
Reviewing the Potential of Psychedelics for the Treatment of PTSD.	7
Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.....	7
Annual Research Review: Defining and treating pediatric treatment-resistant depression.	7
Management of Treatment-Resistant Depression: Challenges and Strategies.	7
The emergence of ketamine as a novel treatment for posttraumatic stress disorder.....	7
Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders.	8
Searching for Treatments for Cocaine Use Disorder: The Quest Continues.....	8
Staging Treatment Intensity and Defining Resistant Depression: Historical Overview and Future Directions.	8
Treatment for Substance Use Disorder With Co-Occurring Mental Illness.	8
Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.....	8
KETAMINE AS A POSSIBLE MODERATOR OF HYPNOTIZABILITY: A FEASIBILITY STUDY.	8
The Combination of Long-term Ketamine and Extinction Training Contributes to Fear Erasure by Bdnf Methylation.	9
Ketamine-A Narrative Review of Its Uses in Medicine.	9

Top Articles

Ketamine Assisted Psychotherapy (KAP): Patient Demographics, Clinical Data and Outcomes in Three Large Practices Administering Ketamine with Psychotherapy.

Academic Journal

(English) By: Dore J; Turnipseed B; Dwyer S; Turnipseed A; Andries J; Ascani G; Monnette C; Huidekoper A; Strauss N; Wolfson P, Journal of psychoactive drugs [J Psychoactive Drugs], ISSN: 2159-9777, 2019 Apr-Jun; Vol. 51 (2), pp. 189-198; Publisher: Taylor & Francis; PMID: 30917760;

Subjects: Hallucinogens administration & dosage; Ketamine administration & dosage; Psychotherapy methods; Adult: 19-44 years; All Adult: 19+ years; Female; Male

A Single Ketamine Infusion Combined With Motivational Enhancement Therapy for Alcohol Use Disorder: A Randomized Midazolam-Controlled Pilot Trial.

Academic Journal

(English) By: Dakwar E; Levin F; Hart CL; Basaraba C; Choi J; Pavlicova M; Nunes EV, The American journal of psychiatry [Am J Psychiatry], ISSN: 1535-7228, 2020 Feb 01; Vol. 177 (2), pp. 125-133; Publisher: American Psychiatric Association; PMID: 31786934;

Subjects: Alcoholism therapy; Ketamine administration & dosage; Ketamine therapeutic use; Psychotherapy methods; Middle Aged: 45-64 years; All Adult: 19+ years; Female; Male

d-Serine is a potential biomarker for clinical response in treatment of post-traumatic stress disorder using (R,S)-ketamine infusion and TIMBER psychotherapy: A pilot study.

Academic Journal

(English) By: Pradhan B; Mitrev L; Moaddell R; Wainer IW, Biochimica et biophysica acta. Proteins and proteomics [Biochim Biophys Acta Proteins Proteom], ISSN: 1570-9639, 2018 Jul; Vol. 1866 (7), pp. 831-839; Publisher: Elsevier; PMID: 29563072;

Subjects: Ketamine therapeutic use; Mindfulness; Serine blood; Stress Disorders, Post-Traumatic therapy; Adult: 19-44 years; Middle Aged: 45-64 years; All Adult: 19+ years; Female; Male

Subanesthetic Dose Ketamine in Posttraumatic Stress Disorder: A Role for Reconsolidation During Trauma-Focused Psychotherapy?

Academic Journal

(English) By: Veen C; Jacobs G; Philippens I; Vermetten E, Current topics in behavioral neurosciences [Curr Top Behav Neurosci], ISSN: 1866-3370, 2018; Vol. 38, pp. 137-162; Publisher: Springer; PMID: 29637527;

Subjects: Stress Disorders, Post-Traumatic

Toward specific ways to combine ketamine and psychotherapy in treating depression.

Academic Journal

(English) By: Hasler G, CNS spectrums [CNS Spectr], ISSN: 1092-8529, 2020 Jun; Vol. 25 (3), pp. 445-447; Publisher: Cambridge University Press; PMID: 31213212;

A proof-of-concept investigation into ketamine as a pharmacological treatment for alcohol dependence: study protocol for a randomised controlled trial.

Academic Journal

(English) By: McAndrew A; Lawn W; Stevens T; Porffy L; Brandner B; Morgan CJ, Trials [Trials], ISSN: 1745-6215, 2017 Apr 04; Vol. 18 (1), pp. 159; Publisher: BioMed Central; PMID: 28372596;

Intranasal Ketamine and Cognitive-Behavioral Therapy for Treatment-Refractory Obsessive-Compulsive Disorder.

Report

(English) By: Adams TG; Bloch MH; Pittenger C, Journal of clinical psychopharmacology [J Clin Psychopharmacol], ISSN: 1533-712X, 2017 Apr; Vol. 37 (2), pp. 269-271; Publisher: Williams And Wilkins; PMID: 28121735

Subjects: Antidepressive Agents pharmacology; Cognitive Behavioral Therapy methods; Depressive Disorder, Major therapy; Ketamine pharmacology; Obsessive-Compulsive Disorder therapy; Adult: 19-44 years; Young Adult: 19-24 years; All Adult: 19+ years; Male

Cognitive Behavior Therapy May Sustain Antidepressant Effects of Intravenous Ketamine in Treatment-Resistant Depression.

Academic Journal

(English) By: Wilkinson ST; Wright D; Fasula MK; Fenton L; Griep M; Ostroff RB; Sanacora G, Psychotherapy and psychosomatics [Psychother Psychosom], ISSN: 1423-0348, 2017; Vol. 86 (3), pp. 162-167; Publisher: Karger; PMID: 28490030;

Subjects: Antidepressive Agents pharmacology; Cognitive Behavioral Therapy methods; Depressive Disorder, Major therapy; Depressive Disorder, Treatment-Resistant therapy; Ketamine pharmacology; Adult: 19-44 years; Middle Aged: 45-64 years; Young Adult: 19-24 years; All Adult: 19+ years; Female; Male

Treatment escalation in patients not responding to pharmacotherapy, psychotherapy, and electro-convulsive therapy: experiences from a novel regimen using intravenous S-ketamine as add-on therapy in treatment-resistant depression.

Academic Journal

(English) By: Kallmünzer B; Volbers B; Karthaus A; Tektas OY; Kornhuber J; Müller HH, Journal of neural transmission (Vienna, Austria : 1996) [J Neural Transm (Vienna)], ISSN: 1435-1463, 2016 May; Vol. 123 (5), pp. 549-52; Publisher: Springer-Verlag; PMID: 26721476;

Subjects: Antidepressive Agents therapeutic use; Depressive Disorder, Treatment-Resistant therapy; Electroconvulsive Therapy methods; Excitatory Amino Acid Antagonists therapeutic use; Ketamine therapeutic use; Psychotherapy methods; Aged: 65+ years; Middle Aged: 45-64 years; All Adult: 19+ years; Female; Male

Can exposure-based CBT extend the effects of intravenous ketamine in obsessive-compulsive disorder? an open-label trial.

Report

(English) By: Rodriguez CI; Wheaton M; Zwerling J; Steinman SA; Sonnenfeld D; Galfalvy H; Simpson HB, The Journal of clinical psychiatry [J Clin Psychiatry], ISSN: 1555-2101, 2016 Mar; Vol. 77 (3), pp. 408-9; Publisher: Physicians Postgraduate Press; PMID: 27046314

Subjects: Cognitive Behavioral Therapy methods; Implosive Therapy methods; Ketamine administration & dosage; Ketamine therapeutic use; Obsessive-Compulsive Disorder drug therapy; Obsessive-Compulsive Disorder therapy; Adolescent: 13-18 years; Adult: 19-44 years; Middle Aged: 45-64 years; Young Adult: 19-24 years; All Child: 0-18 years; All Adult: 19+ years

PsychINFO

Translating molecular and neuroendocrine findings in posttraumatic stress disorder and resilience to novel therapies.

Academic Journal

DePierro, Jonathan; Lepow, Lauren; Feder, Adriana; Yehuda, Rachel; *Biological Psychiatry*, Vol 86(6), Sep 15, 2019 pp. 454-463. Publisher: Elsevier Science; [Journal Article] Subjects: Drug Therapy; Neurobiology; Posttraumatic Stress Disorder; Resilience (Psychological)

Exploring brain-derived neurotrophic factor Val66Met polymorphism and extinction learning-based treatment outcome in obsessive-compulsive disorder: A pilot study.

Academic Journal

Linkovski, Omer; Wheaton, Michael G.; Zwerling, Jordana; Odgerel, Zagaa; van Roessel, Peter; Filippou-Frye, Maria; Lombardi, Anthony; Wright, Brianna; Steinman, Shari A.; Simpson, Helen Blair; Lee, Francis; Rodriguez, Carolyn I.; *Journal of Clinical Psychopharmacology*, Vol 39(1), Jan-Feb, 2019 pp. 91-93. Publisher: Lippincott Williams & Wilkins; [Letter]

Subjects: Brief Psychotherapy; Cognitive Behavior Therapy; Ketamine; Polymorphism; Brain Derived Neurotrophic Factor; Adulthood (18 yrs & older)

Ketamine abuse potential and use disorder.

Academic Journal

Liu, Yu; Lin, Deyong; Wu, Boliang; Zhou, Wenhua; *Brain Research Bulletin*, Vol 126(Part 1), Sep, 2016 pp. 68-73. Publisher: Elsevier Science; [Journal Article]

Subjects: Antidepressant Drugs; Ketamine; Pharmacology

Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?

Academic Journal

Majić, Tomislav; Schmidt, Timo T.; Gallinat, Jürgen; *Journal of Psychopharmacology*, Vol 29(3), Mar, 2015 pp. 241-253. Publisher: Sage Publications; [Journal Article]

Subjects: Drug Abuse; Hallucinations; Ketamine; Obsessive Compulsive Disorder; Psychotherapy

Medline

Reviewing the Potential of Psychedelics for the Treatment of PTSD.

Academic Journal

(English) By: Krediet E; Bostoën T; Breeksema J; van Schagen A; Passie T; Vermetten E, The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol], ISSN: 1469-5111, 2020 Jun 24; Vol. 23 (6), pp. 385-400; Publisher: Oxford University Press; PMID: 32170326;

© The Author(s) 2020. Published by Oxford University Press on behalf of CINP.

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments.

Academic Journal

(English) By: Greenway KT; Garel N; Jerome L; Feduccia AA, Expert review of clinical pharmacology [Expert Rev Clin Pharmacol], ISSN: 1751-2441, 2020 Jun 01, pp. 1-15; Publisher: Taylor & Francis; PMID: 32478631;

Annual Research Review: Defining and treating pediatric treatment-resistant depression.

Academic Journal

(English) By: Dwyer JB; Stringaris A; Brent DA; Bloch MH, Journal of child psychology and psychiatry, and allied disciplines [J Child Psychol Psychiatry], ISSN: 1469-7610, 2020 Mar; Vol. 61 (3), pp. 312-332; Publisher: Blackwell Publishers; PMID: 32020643;

Management of Treatment-Resistant Depression: Challenges and Strategies.

Academic Journal

(English) By: Voineskos D; Daskalakis ZJ; Blumberger DM, Neuropsychiatric disease and treatment [Neuropsychiatr Dis Treat], ISSN: 1176-6328, 2020 Jan 21; Vol. 16, pp. 221-234; Publisher: Dove Medical Press; PMID: 32021216;

The emergence of ketamine as a novel treatment for posttraumatic stress disorder.

Academic Journal

(English) By: Feder A; Rutter SB; Schiller D; Charney DS, Advances in pharmacology (San Diego, Calif.) [Adv Pharmacol], ISSN: 1557-8925, 2020; Vol. 89, pp. 261-286; Publisher: Academic Press; PMID: 32616209;

© 2020 Elsevier Inc. All rights reserved.

Novel pharmacological targets in drug development for the treatment of anxiety and anxiety-related disorders.

Academic Journal

(English) By: Sartori SB; Singewald N, Pharmacology & therapeutics [Pharmacol Ther], ISSN: 1879-016X, 2019 Dec; Vol. 204, pp. 107402; Publisher: Pergamon Press; PMID: 31470029;

Searching for Treatments for Cocaine Use Disorder: The Quest Continues.

Editorial & Opinion

(English) By: Brady KT, The American journal of psychiatry [Am J Psychiatry], ISSN: 1535-7228, 2019 Nov 01; Vol. 176 (11), pp. 892-893; Publisher: American Psychiatric Association; PMID: 31672040

Subjects: Cocaine; Cocaine-Related Disorders; Ketamine; Mindfulness; Substance-Related Disorders

Staging Treatment Intensity and Defining Resistant Depression: Historical Overview and Future Directions.

Academic Journal

(English) By: Salloum NC; Papakostas GI, The Journal of clinical psychiatry [J Clin Psychiatry], ISSN: 1555-2101, 2019 Jun 04; Vol. 80 (4); Publisher: Physicians Postgraduate Press; PMID: 31163105;

Subjects: Antidepressive Agents classification; Antidepressive Agents history; Antidepressive Agents pharmacology; Depressive Disorder, Treatment-Resistant diagnosis; Depressive Disorder, Treatment-Resistant drug therapy; Depressive Disorder, Treatment-Resistant history

Treatment for Substance Use Disorder With Co-Occurring Mental Illness.

Academic Journal

(English) By: Iqbal MN; Levin CJ; Levin FR, Focus (American Psychiatric Publishing) [Focus (Am Psychiatr Publ)], ISSN: 1541-4094, 2019 Apr; Vol. 17 (2), pp. 88-97; Publisher: American Psychiatric Pub; PMID: 31975963;

Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development.

Academic Journal

(English) By: Schenberg EE, Frontiers in pharmacology [Front Pharmacol], ISSN: 1663-9812, 2018 Jul 05; Vol. 9, pp. 733; Publisher: Frontiers Media]; PMID: 30026698;

KETAMINE AS A POSSIBLE MODERATOR OF HYPNOTIZABILITY: A FEASIBILITY STUDY.

Academic Journal

(English) By: Patterson DR; Hoffer C; Jensen MP; Wiechman SA; Sharar SR, The International journal of clinical and experimental hypnosis [Int J Clin Exp Hypn], ISSN: 1744-5183, 2018 Jul-Sep; Vol. 66 (3), pp. 298-307; Publisher: Routledge; PMID: 29856288;

Subjects: Anesthetics, Dissociative therapeutic use; Hypnosis methods; Ketamine therapeutic use; Adult: 19-44 years; Middle Aged: 45-64 years; Young Adult: 19-24 years; All Adult: 19+ years; Female; Male

The Combination of Long-term Ketamine and Extinction Training Contributes to Fear Erasure by Bdnf Methylation.

Academic Journal

(English) By: Ju LS; Yang JJ; Lei L; Xia JY; Luo D; Ji MH; Martynyuk AE; Yang JJ, Frontiers in cellular neuroscience [Front Cell Neurosci], ISSN: 1662-5102, 2017 Apr 20; Vol. 11, pp. 100; Publisher: Frontiers Research Foundation; PMID: 28473755;

Ketamine-A Narrative Review of Its Uses in Medicine.

Academic Journal

(English) By: Radvansky BM; Puri S; Sifonios AN; Eloy JD; Le V, American journal of therapeutics [Am J Ther], ISSN: 1536-3686, 2016 Nov/Dec; Vol. 23 (6), pp. e1414-e1426; Publisher: Lippincott Williams & Wilkins; PMID: 25923225;

Subjects: Excitatory Amino Acid Antagonists therapeutic use; Ketamine therapeutic use; Receptors, N-Methyl-D-Aspartate antagonists & inhibitors